Principal Healthcare Innovators Index (BTEC)

$37.26 0.08 (0.21%)

9:33 EDT BTEC Stock Quote Delayed 30 Minutes

3 Stocks To Buy For Earnings Announcement Returns

By Tezcan Gecgil, InvestorPlace Contributor Oct 27, 2020

With the latest quarterly results season well underway, let's take a look at 3 stocks to buy for earnings announcement returns.

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

7 of the Best Biotech ETFs

7 Best Healthcare ETFs for the Rest of 2018

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 252

Day's Range $37.26 - $37.26

52-Week Range $28.18 - $40.86

Dividend & Yield N/A (N/A)

BTEC Stock Predictions, Articles, and Principal Healthcare Innovators Index News

From the Web

Biotech ETFs To Benefit From Latest Booster Update

From Talk Markets Aug 21, 2021

Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from Sept. 20 onward. Here's ETFs that may benefit.

Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines

From Talk Markets May 8, 2021

The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from the recent development:

Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

From Talk Markets Nov 18, 2020

The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has once again come up with encouraging study data relating to mRNA-1273.

3 Health Care ETFs Where Components Are Enduring Downgrades

From Benzinga Sep 25, 2020

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing. What Happened: It could...

3 ETFs To Play Gilead's $21B Immunomedics Takeover

From Benzinga Sep 14, 2020

Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion. That...

Moderna ETFs To Gain On New Positive COVID-19 Vaccine Data

From Talk Markets Aug 28, 2020

The competition to come up with a coronavirus vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna.